{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:05:36Z","timestamp":1792195536439,"version":"4.4.0"},"reference-count":43,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["R01CA111999"],"award-info":[{"award-number":["R01CA111999"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,3,26]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen\u2013loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes. We hypothesized that the combined transfer of TIL, containing a melanoma antigen recognized by T cells 1 (MART-1) specific population, with MART-1-pulsed DC will result in enhanced proliferation and prolonged survival of transferred MART-1 specific T cells in vivo ultimately leading to improved clinical responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We tested the combination of TIL and DC in a phase II clinical trial of patients with advanced stage IV melanoma. HLA-A0201 patients whose early TIL cultures demonstrated reactivity to MART-1 peptide were randomly assigned to receive TIL alone or TIL +DC pulsed with MART-1 peptide. The primary endpoint was to evaluate the persistence of MART-1 TIL in the two arms. Secondary endpoints were to evaluate clinical response and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten patients were given TIL alone while eight patients received TIL+DC vaccine. Infused MART-1 reactive CD8\n                      <jats:sup>+<\/jats:sup>\n                      TIL were tracked in the blood over time by flow cytometry and results show good persistence in both arms, with no difference in the persistence of MART-1 between the two arms. The objective response rate was 30% (3\/10) in the TIL arm and 50% (4\/8) in the TIL+DC arm. All treatments were well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of TIL +DC showed no difference in the persistence of MART-1 TIL compared with TIL therapy alone. Although more patients showed a clinical response to TIL+DC therapy, this study was not powered to resolve differences between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00338377\">NCT00338377<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-002449","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T12:16:16Z","timestamp":1621599376000},"page":"e002449","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00338377","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00338377","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00338377","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-2428","authenticated-orcid":false,"given":"Chantal","family":"Saberian","sequence":"first","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Najjar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo G.","family":"Radvanyi","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Ontario Institute for Cancer Research, Ontario, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara L.","family":"Haymaker","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Andr\u00e9e","family":"Forget","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana C.","family":"Faria","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7765","authenticated-orcid":false,"given":"Isabella C.","family":"Glitza","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Parshottam","sequence":"additional","affiliation":[{"name":"Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Prieto","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Liz\u00e9e","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna","family":"Patel","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-2856","authenticated-orcid":false,"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-3460","authenticated-orcid":false,"given":"Chantale","family":"Bernatchez","sequence":"additional","affiliation":[{"name":"Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"2025100310224229000_9.5.e002449.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"2025100310224229000_9.5.e002449.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3649"},{"key":"2025100310224229000_9.5.e002449.3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100310224229000_9.5.e002449.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279"},{"key":"2025100310224229000_9.5.e002449.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102"},{"key":"2025100310224229000_9.5.e002449.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8"},{"key":"2025100310224229000_9.5.e002449.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722"},{"key":"2025100310224229000_9.5.e002449.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1177"},{"key":"2025100310224229000_9.5.e002449.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"2025100310224229000_9.5.e002449.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0380"},{"key":"2025100310224229000_9.5.e002449.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220"},{"key":"2025100310224229000_9.5.e002449.12","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31826e8f5f"},{"key":"2025100310224229000_9.5.e002449.13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848"},{"key":"2025100310224229000_9.5.e002449.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7125"},{"key":"2025100310224229000_9.5.e002449.15","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.157"},{"key":"2025100310224229000_9.5.e002449.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2025100310224229000_9.5.e002449.17","doi-asserted-by":"publisher","DOI":"10.1038\/32588"},{"key":"2025100310224229000_9.5.e002449.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.01.005"},{"key":"2025100310224229000_9.5.e002449.19","doi-asserted-by":"publisher","DOI":"10.1038\/ni0104-7"},{"key":"2025100310224229000_9.5.e002449.20","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120025091"},{"key":"2025100310224229000_9.5.e002449.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1722"},{"key":"2025100310224229000_9.5.e002449.22","doi-asserted-by":"publisher","DOI":"10.4161\/onci.18851"},{"key":"2025100310224229000_9.5.e002449.23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0215"},{"key":"2025100310224229000_9.5.e002449.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1621"},{"key":"2025100310224229000_9.5.e002449.25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100310224229000_9.5.e002449.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4121"},{"key":"2025100310224229000_9.5.e002449.27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3092","article-title":"Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer","volume":"34","author":"Nesselhut","year":"2016","journal-title":"JCO"},{"key":"2025100310224229000_9.5.e002449.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1254"},{"key":"2025100310224229000_9.5.e002449.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1575-2"},{"key":"2025100310224229000_9.5.e002449.30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1792058","article-title":"Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination","volume":"9","author":"L\u00f6vgren","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100310224229000_9.5.e002449.31","first-page":"5265","article-title":"Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope","volume":"54","author":"Cole","year":"1994","journal-title":"Cancer Res"},{"key":"2025100310224229000_9.5.e002449.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.6548"},{"key":"2025100310224229000_9.5.e002449.33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1989.7.2.250"},{"key":"2025100310224229000_9.5.e002449.34","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1801"},{"key":"2025100310224229000_9.5.e002449.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1261"},{"key":"2025100310224229000_9.5.e002449.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.4254"},{"key":"2025100310224229000_9.5.e002449.37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000668"},{"key":"2025100310224229000_9.5.e002449.38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2518","article-title":"Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1","volume":"37","author":"Sarnaik","year":"2019","journal-title":"JCO"},{"key":"2025100310224229000_9.5.e002449.39","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(19990225)87:1<37::AID-CNCR7>3.0.CO;2-7","article-title":"Melanoma-Associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration","volume":"87","author":"Fetsch","year":"1999","journal-title":"Cancer"},{"key":"2025100310224229000_9.5.e002449.40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444499"},{"key":"2025100310224229000_9.5.e002449.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514"},{"key":"2025100310224229000_9.5.e002449.42","unstructured":"Kucuk A , Topkan E , Ikiz ED . Combination of stereotactic radiosurgery with immunotherapy: is it a new treatment option for brain metastases? Int J Oncol 2020:9\u201319."},{"key":"2025100310224229000_9.5.e002449.43","doi-asserted-by":"crossref","unstructured":"Chow MT , M\u00f6ller A , Smyth MJ . Inflammation and immune surveillance in cancer. seminars in cancer biology. Elsevier, 2012.","DOI":"10.1016\/j.semcancer.2011.12.004"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:22:51Z","timestamp":1759512171000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,21]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jitc-2021-002449"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002449","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}